Kalaris Therapeutics Inc
Support and Resistance Levels
Past performance
News About KLRS
All events for KLRS
All deals for KLRS
Financial Ratios
Financial Statements
KLRS vs Sector & Peers
About Kalaris Therapeutics Inc
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases. Website kalaristx.com
Headquarters Berkeley Heights, NJ, US